- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02921386
The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate
A Phase 2 Study of the Effect of Meals With Various Amounts of Fat Given Immediately After Dosing on the Pharmacokinetics of an Oral Testosterone Undecanoate
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 2, open-label, randomized, cross over, pharmacokinetic study. Subjects will initially be dosed for 2 weeks (Run-In Phase) to allow suppression of endogenous testosterone production, while allowing the oral TU to reach steady state. The subjects will then be confined to a clinical unit in which they undergo the PK Phase of the study. During the PK Phase of the study, subjects will undergo a five-period cross-over in which oral TU is dosed twice daily. Subjects will dose in the morning and in the evening immediately prior to protocol-defined meals. The protocol-defined breakfasts will contain various levels of fat including 15 g, 30 g, 45 g, a breakfast consistent with the fat and calorie content of the high-fat breakfast consistent with recommendations in the Guidance for Industry on Food-Effect Bioavailability and Fed Bioequivalence Studies (December 2002), or while fasting (with no meal until 4 hours post-dose). Subjects will be randomized to a designated sequence of the protocol-defined breakfasts, or the fasted state. The subjects will be required to consume the entire breakfast within 20 minutes during the PK Phase. The protocol-defined evening meal will be required to be consumed within 20 minutes. The 5 meal periods will occur on sequential days.
Approximately twenty (20) subjects will be enrolled in order to ensure completion of 16 subjects.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Torrance, California, United States, 90502
- Harbor-UCLA Medical Center
-
-
Florida
-
Orlando, Florida, United States, 32809-3017
- Orlando Clinical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Man 18 to 65 years of age, inclusive, with a clinical diagnosis of hypogonadism (signs/symptoms consistent with hypogonadism for testosterone naïve subjects and history of signs/symptoms for subjects who have received prior treatment) as well as testosterone levels consistent with hypogonadism as defined by 2 morning total T values of <300 ng/dL (between 6:00 and 10:00 AM drawn on 2 separate days [approximately 7 (±2) days apart].
- Adequate venous access in the left or right arm to allow collection of a number of blood samples via a venous cannula.
- Must be naïve to androgen-replacement therapy or washed out of prior androgen replacement therapies; that is, be willing to cease current T treatment or currently not be taking T treatment, (washout durations specified in exclusion criterion #1). Subjects must remain off all forms of T, except for dispensed study drug, throughout the entire study.
- Subjects on replacement therapy for hypopituitarism or multiple endocrine deficiencies must be on stable doses of thyroid hormone and adrenal replacement hormones for at least 14 days before Screen 1.
- Has voluntarily given written informed consent to participate in this study.
Exclusion Criteria:
- Received oral topical (eg, gel or patch), intranasal, or buccal T therapy within the previous 2 weeks, intramuscular T injection of short-acting duration (eg, T enanthate, T cypionate) within the previous 4 weeks, intramuscular T injection of long-acting duration (eg, AVEED) within the previous 20 weeks, or T implantable pellets (Testopel®) within the previous 6 months.
- Has an intercurrent disease deemed clinically significant in the opinion of the investigator of any type; in particular, liver, kidney, uncontrolled or poorly controlled heart disease, including hypertension, congestive heart failure or coronary heart disease, or psychiatric-illness, including severe depression.
- Has had a recent (within 2 years) history of stroke, transient ischemic attack, or acute coronary event.
- Has a mean of the triplicate assessment of sBP > 150 mm Hg and/or dBP > 90 mm Hg at screening (if prescribed antihypertensives, subject should be taking medications on the day of the screening visit with a sip of water). Subjects < 60 years of age and prescribed antihypertensives will be excluded if the mean of the triplicate assessment of sBP > 140 mm Hg and/or dBP > 90 mm Hg at screening.
- Has had recent (within 2 years) history of angina or stent (coronary or carotid) placement.
- Has untreated, severe obstructive sleep apnea.
- Has clinically significant abnormal laboratory values, including serum transaminases > 2 × upper limits of normal (ULN), serum bilirubin > 1.5 × ULN and serum creatinine > 1.5 × ULN.
- Has a hematocrit (HCT) value of < 35% or > 48%.
- Has a history of polycythemia, either idiopathic or associated with TRT treatment.
- Is a diabetic subject with a glycosylated hemoglobin > 8.5%.
- Has a body mass index (BMI) ≥ 38 kg/m2.
- Has been on stable doses of antihypertensive medication for < 3 months.
- Has an abnormal prostate digital rectal examination [(DRE); palpable nodules], elevated PSA (serum PSA > 4.0 ng/mL), I-PSS > 19 points at screening, and/or history of, or current or suspected, prostate cancer.
- Has a history of, or current or suspected, breast cancer.
- Has a history of abnormal bleeding tendencies or thrombophlebitis unrelated to venipuncture or intravenous cannulation within the previous 2 years.
- Use of dietary supplements such as saw palmetto or phytoestrogens and any dietary supplements that may increase total T, such as androstenedione or dehydroepiandrosterone within the previous 4 weeks.
- Has known malabsorption syndrome and/or current treatment with oral lipase inhibitors (eg, orlistat [Xenical®]) and/or bile acid-binding resins (eg, cholestyramine [Questran®], colestipol [Colestid®]) or treatments that promote gastric emptying (eg, metoclopramide [Reglan®]).
- Inability to observe all rules and smoking restrictions in place at the clinical facility during confinement.
- Has history of abuse of alcohol or any drug substance within the previous 2 years.
- Poor compliance or unlikely to keep clinic appointments and remain for entire confinement period.
- Has received any drug as part of another research study within 30 days of initial dose administration in this study.
- Donated blood (≥ 500 mL) within the 12-week period before the initial study dose.
- Current use of the following groups of drugs that effect T levels, T metabolism or levels of T metabolites, namely antiandrogens, 5-alpha-reductase inhibitors (eg, dutasteride, finasteride), estrogens, long-acting opioid analgesics (eg, methadone hydrochloride, buprenorphine hydrochloride) or human growth hormone (HGH).
- Unwilling or unable to follow the dietary requirements for this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Breakfast A - Fasting
Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.
|
All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
|
OTHER: Breakfast B - 15 g fat
Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.
|
All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
|
OTHER: Breakfast C - 30 g fat
Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.
|
All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
|
OTHER: Breakfast D - 45 g fat
Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.
|
All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
|
OTHER: Breakfast E - High Fat
Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.
|
All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax-am for Oral TU Across Breakfast With Varying Fat Content
Time Frame: 0, 1, 2, 3, 4, 6, 8, 12 hours post-dose
|
Peak Concentration after morning dose (Cmax) for oral testosterone undecanoate taken after a fasting breakfast of varying fat content.
|
0, 1, 2, 3, 4, 6, 8, 12 hours post-dose
|
Time of Peak Concentration (Tmax-am)
Time Frame: 12 hours
|
The time of peak concentration (Tmax-am) will be assessed within each relevant dosing interval.
|
12 hours
|
Area Under the Curve (AUC-am)
Time Frame: 0, 1, 2, 3, 4, 6, 8, 12 hours post-dose
|
The 12 hours following morning dose area under the curve (AUC) will assessed for each sequence of breakfasts with varying fat content.
|
0, 1, 2, 3, 4, 6, 8, 12 hours post-dose
|
Time Weighted Average Total Testosterone Concentration (Cavg-am)
Time Frame: 12 hours
|
The time weighted average of total testosterone concentration will be assessed for each dosing interval.
|
12 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ronald Swerdloff, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Gonadal Disorders
- Hypogonadism
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Androgens
- Anabolic Agents
- Testosterone
- Methyltestosterone
- Testosterone undecanoate
- Testosterone enanthate
- Testosterone 17 beta-cypionate
Other Study ID Numbers
- CLAR-16015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypogonadism
-
Rigshospitalet, DenmarkTerminatedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleDenmark
-
Shanghai Jiao Tong University School of MedicineUnknownIdiopathic Hypogonadotropic Hypogonadism
-
Endo PharmaceuticalsCompletedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleUnited States
-
Clarus Therapeutics, Inc.CompletedMale Hypogonadism | Secondary Hypogonadism | Primary HypogonadismUnited States
-
Amneal Pharmaceuticals, LLCPhase One Solutions, Inc.CompletedHypogonadotropic Hypogonadism | Primary HypogonadismUnited States
-
Endo PharmaceuticalsCompletedHypogonadism | Secondary Hypogonadism | Primary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedObesity | Acquired Hypogonadotropic HypogonadismUnited States
-
Massachusetts General HospitalRecruiting
-
Mereo BioPharmaCompleted
-
Organon and CoCompleted
Clinical Trials on Oral Testosterone Undecanoate
-
Clarus Therapeutics, Inc.Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterCompletedHypogonadismUnited States
-
Clarus Therapeutics, Inc.Completed
-
Clarus Therapeutics, Inc.CompletedMale HypogonadismUnited States, Germany
-
Clarus Therapeutics, Inc.Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; PharmaN...CompletedMale HypogonadismUnited States, Germany
-
Clarus Therapeutics, Inc.Syneos HealthCompletedHypogonadismUnited States
-
San Diego Sexual MedicineNot yet recruitingHypoactive Sexual Desire DisorderUnited States
-
Clarus Therapeutics, Inc.inVentiv Health ClinicalCompleted
-
Lipocine Inc.PPD; Syneos HealthCompleted
-
Clarus Therapeutics, Inc.CompletedMale HypogonadismUnited States, Canada
-
Merck Sharp & Dohme LLCCompletedHypogonadism | Androgens